Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer

International Journal of Clinical Oncology

Volumn 12, Issue 1, 2007, Pages 31-36

  Secord, Angeles Alvarez ^a   Havrilesky, Laura J ^a   Carney, Michael E ^b   Soper, John T ^a   Clarke Pearson, Daniel L ^a   Rodriguez, Gustavo C ^c   Berchuck, Andrew ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cervical cancer; Chemotherapy; Endometrial cancer

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMBINATION CHEMOTHERAPY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LOW DRUG DOSE; LUNG DISEASE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CARCINOSARCOMA; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NORTH CAROLINA; PACLITAXEL; PILOT PROJECTS; TREATMENT OUTCOME; UTAH; UTERINE CERVICAL NEOPLASMS;

EID: 33947506455     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-006-0619-9     Document Type: Article

References (21)

1. American Cancer Society 2004 Cancer facts and figures 2004 American Cancer Society Atlanta, Ga
2. GA Omura JA Blessing L Vaccarello 1997 Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 15 165 171
3. DH Moore JA Blessing RP McQuellon 2004 Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 22 3113 3119
4. HG Ball JA Blessing SS Lentz 1996 A phase II trial of taxol in advanced and recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study Gynecol Oncol 62 278 281
5. GF Fleming VL Brunetto D Cella 2004 Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 22 2159 2166
6. M Markman 2000 Weekly paclitaxel in the management of ovarian cancer Semin Oncol 2 37 40
7. LJ Havrilesky AA Alvarez RA Sayer 2003 Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer Gynecol Oncol 88 51 57
8. AB Miller B Hoogstraten M Staquet 1981 Reporting results of cancer treatment Cancer 47 207 214
9. M Markman A Kennedy K Webster 2000 Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center J Clin Oncol 18 102 105
10. PJ Hoskins KD Swenerton JA Pike 2001 Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study J Clin Oncol 19 4048 4053
11. KA Moller PA Gehrig L Van Le 2004 The role of optimal debulking in advanced stage serous carcinoma of the uterus Gynecol Oncol 94 170 174
12. CH Wu CH Yang JN Lee 2001 Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects Int J Gynecol Cancer 11 295 299
13. DY Yu GV Dahl RS Shames 2001 Weekly dosing of carboplatin increases risk of allergy in children J Pediatr Hematol Oncol 23 349 352
14. A Polyzos N Tsavaris C Kosmas 2001 Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience Oncology 61 129 133
15. CB Broome RI Schiff HS Friedman 1996 Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions Med Pediatr Oncol 26 105 110
16. MA Socinski A Ivanova K Bakri 2006 A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-week carboplatin and weekly paclitaxel in advanced non-small cell lung cancer Ann Oncol 17 104 109
17. Belani CP, Larocca RV, Rinaldi DA, et al. (2004) A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs standard paclitaxel and carboplatin given every 3 weeks, followed by weekly paclitaxel. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22:a7017
18. W Schuette T Blankenburg W Guschall 2006 Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin Clin Lung Cancer 7 338 343
19. Seidman AD, Berry D, Cirrincione C, et al. (2004) CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22:a512
20. MC Green AU Buzdar T Smith 2005 Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks J Clin Oncol 23 5983 5992
21. P Rosenberg H Andersson K Boman 2002 Randomized trial of single agent paclitaxel given weekly versus every 3 weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum Acta Oncologica 41 418 424